Rapid response for pandemics: single cell sequencing and deep learning to predict antibody sequences against an emerging antigen

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3R01AI169543-01S1

Grant search

Key facts

  • Disease

    Disease X
  • Start & end year

    2021.0
    2025.0
  • Known Financial Commitments (USD)

    $1,219,945
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    ASSOCIATE PROFESSOR Jeniffer Hernandez
  • Research Location

    United States of America
  • Lead Research Institution

    KECK GRADUATE INST OF APPLIED LIFE SCIS
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

ABSTRACT One of the "holy grails" in immunology is to be able to directly predict tight-binding variable chain antibody sequences in silico against foreign or non-self `antigenic' proteins. Immunoglobulin chain rearrangement can potentially encode approximately 1016 different variants of antibody heavy and light chain sequences. However, only a small fraction of the sequence space is generally accessed for evolving antibodies against foreign proteins. The computational challenge is to go from a model of the structure of an antigen to predicting a set of antibody chain sequences that can bind tightly to the antigen. If solved, it might be possible to move in less than 24 hours from the first cryo-electron-microscopic structure of a novel viral protein to advance a set of potent antibody-like molecular candidates for testing. Towards solving this problem, this project aims to develop a deep learning architecture that will take as input thermodynamic, quantum mechanical (density functional), and local structure- based network topographical features of the antigens and their cognate antibodies, and will output their respective binding affinity constants. We will design a generative adversarial network (GAN), which we think is uniquely suited for regression-based ML approaches for the immune system, to discover associations between the epitope and the variable chain features. This approach requires a large data stream of antigen and cognate antibody sequences, which until recently was difficult to obtain. A recently described single B-cell receptor (BCR) specific tagging method coupled with single cell deep sequencing ("linking B cell receptor to antigen specificity through sequencing" or LIBRA- seq) can rapidly isolate and sequence the BCR variable chain coding regions that can bind with high selectivity to antigenic epitopes. Towards the specific project goals, in Task 1, LIBRA-seq will be used to rapidly identify and generate candidate immunoglobulin coding sequences in response to specific linear and nonlinear epitopes (against controls), chosen through computational/molecular modeling and prioritized with SARS-CoV-2 Spike protein epitopes (but not restricted to these), injected into a mouse model, to generate large training sets; in Task 2, these training sets, along with other data sets already available in public databases, will generate a series of structural features (described above), which will be used to train the GAN; in Task 3, the predicted epitope-antibody interactions will be validated by direct experiments with synthetic antibody and phage-display systems. Thus, the proposed strategy combines foundational principles in evolutionary biology, genomics, structural chemistry, and computer science to the solution of a general biological engineering problem. Results from this project are expected to lay the foundations for a rigorously tested and fully automated machine- learning system that could rapidly generate synthetic antibody candidates from the structure of a novel virus protein, which can enhance the rapid response ability against a future pandemic. The ability to develop targeted antibody therapy against non-infectious or chronic diseases, and on the production of antibody-based industrial enzymes, will also be dramatically enhanced if this project were to be successful. The team: The team-leads of this multi-institutional research project comprise a computer scientist, a protein crystallographer, an immunologist, and a molecular biologist. 1